Slight alteration to what I've written. In one of their ANN's they mention GvHD but not crohns. However in the full report it does mention that Crohns is a secondary and GvHD is the lead and both are Tier 1.
So evidently according to the report Crohns refractory is tier 1.
However they were very specific and well planned in giving us a clear picture on what they are doing with GvHD I'm still interested in what they are doing with Crohns they haven't really provided a lot of info in that area.
Crohns Trial Updates, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |